Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:331 |
|---|---|
| Enthalten in: |
JAMA - 331(2024), 12 vom: 26. März, Seite 1060-1061 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sax, Paul E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 29.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1001/jama.2024.2985 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369172256 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369172256 | ||
| 003 | DE-627 | ||
| 005 | 20240330001101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2024.2985 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM369172256 | ||
| 035 | |a (NLM)38427337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sax, Paul E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 650 | 7 | |a cabotegravir |2 NLM | |
| 650 | 7 | |a HMH0132Z1Q |2 NLM | |
| 650 | 7 | |a Diketopiperazines |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Rilpivirine |2 NLM | |
| 650 | 7 | |a FI96A8X663 |2 NLM | |
| 650 | 7 | |a HIV Integrase Inhibitors |2 NLM | |
| 700 | 1 | |a Thompson, Melanie A |e verfasserin |4 aut | |
| 700 | 1 | |a Saag, Michael S |e verfasserin |4 aut | |
| 700 | 0 | |a IAS-USA Treatment Guidelines Panel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA |d 1948 |g 331(2024), 12 vom: 26. März, Seite 1060-1061 |w (DE-627)NLM000006939 |x 1538-3598 |7 nnns |
| 773 | 1 | 8 | |g volume:331 |g year:2024 |g number:12 |g day:26 |g month:03 |g pages:1060-1061 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jama.2024.2985 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 331 |j 2024 |e 12 |b 26 |c 03 |h 1060-1061 | ||